Literature DB >> 29672679

Disease prediction by cell-free DNA methylation.

Hao Feng1, Peng Jin2, Hao Wu1.   

Abstract

Disease diagnosis using cell-free DNA (cfDNA) has been an active research field recently. Most existing approaches perform diagnosis based on the detection of sequence variants on cfDNA; thus, their applications are limited to diseases associated with high mutation rate such as cancer. Recent developments start to exploit the epigenetic information on cfDNA, which could have substantially wider applications. In this work, we provide thorough reviews and discussions on the statistical method developments and data analysis strategies for using cfDNA epigenetic profiles, in particular DNA methylation, to construct disease diagnostic models. We focus on two important aspects: marker selection and prediction model construction, under different scenarios. We perform simulations and real data analysis to compare different approaches, and provide recommendations for data analysis.
© The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  DNA methylation; cell-free DNA; epigenetics; liquid biopsy; marker selection; predictive modeling

Mesh:

Year:  2019        PMID: 29672679      PMCID: PMC6556903          DOI: 10.1093/bib/bby029

Source DB:  PubMed          Journal:  Brief Bioinform        ISSN: 1467-5463            Impact factor:   11.622


  14 in total

1.  Differential methylation analysis for bisulfite sequencing using DSS.

Authors:  Hao Feng; Hao Wu
Journal:  Quant Biol       Date:  2019-12-15

2.  Cell-free DNA methylation as a potential biomarker in brain disorders.

Authors:  Yulin Jin; Emily G Allen; Peng Jin
Journal:  Epigenomics       Date:  2022-01-17       Impact factor: 4.357

3.  DISMIR: Deep learning-based noninvasive cancer detection by integrating DNA sequence and methylation information of individual cell-free DNA reads.

Authors:  Jiaqi Li; Lei Wei; Xianglin Zhang; Wei Zhang; Haochen Wang; Bixi Zhong; Zhen Xie; Hairong Lv; Xiaowo Wang
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

4.  Cell-free DNA as a biomarker of aging.

Authors:  Yee Voan Teo; Miriam Capri; Cristina Morsiani; Grazia Pizza; Ana Maria Caetano Faria; Claudio Franceschi; Nicola Neretti
Journal:  Aging Cell       Date:  2018-12-20       Impact factor: 9.304

Review 5.  Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy.

Authors:  Chang Zeng; Emily Kunce Stroup; Zhou Zhang; Brian C-H Chiu; Wei Zhang
Journal:  Cancer Commun (Lond)       Date:  2019-03-29

6.  TOAST: improving reference-free cell composition estimation by cross-cell type differential analysis.

Authors:  Ziyi Li; Hao Wu
Journal:  Genome Biol       Date:  2019-09-04       Impact factor: 13.583

7.  Accumulation of Circulating Cell-Free CpG-Enriched Ribosomal DNA Fragments on the Background of High Endonuclease Activity of Blood Plasma in Schizophrenic Patients.

Authors:  E S Ershova; E M Jestkova; A V Martynov; G V Shmarina; P E Umriukhin; L V Bravve; N V Zakharova; G P Kostyuk; D V Saveliev; M D Orlova; M Bogush; S I Kutsev; N N Veiko; S V Kostyuk
Journal:  Int J Genomics       Date:  2019-08-05       Impact factor: 2.326

8.  A deep neural network approach to predicting clinical outcomes of neuroblastoma patients.

Authors:  Léon-Charles Tranchevent; Francisco Azuaje; Jagath C Rajapakse
Journal:  BMC Med Genomics       Date:  2019-12-20       Impact factor: 3.063

Review 9.  Cell-Free DNA Methylation Profiling Analysis-Technologies and Bioinformatics.

Authors:  Jinyong Huang; Liang Wang
Journal:  Cancers (Basel)       Date:  2019-11-06       Impact factor: 6.639

10.  CFEA: a cell-free epigenome atlas in human diseases.

Authors:  Fulong Yu; Kai Li; Shuangquan Li; Jiaqi Liu; Yan Zhang; Meng Zhou; Hengqiang Zhao; Hongyan Chen; Nan Wu; Zhihua Liu; Jianzhong Su
Journal:  Nucleic Acids Res       Date:  2020-01-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.